BioCentury
ARTICLE | Clinical News

AV-101 L-4-chlorokynurenine: Phase IIa started

November 16, 2015 8:00 AM UTC

VistaGen said NIH’s National Institute of Mental Health (NIMH) began a double-blind, placebo-controlled, crossover, U.S. Phase IIa trial to evaluate 1,080 and 1,440 mg oral AV-101 once daily for 14 da...